hit counter
Benitec Biopharma Limited (BNTC) Stock News Sentiment & Price - Sentifly
BNTC - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Benitec Biopharma Limited (BNTC)

Australia
Biotechnology
NASDAQ
BNTC Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BNTC Latest news
PRNewsWire
Neutral
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
2021-09-20 08:00

HAYWARD, Calif., Sept. 20, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today provided an operational update and announced the financial results for its fiscal year ended June 30, 2021.

PRNewsWire
Neutral
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
2021-09-13 15:58

HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A.

PRNewsWire
Neutral
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
2021-09-08 08:10

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design.

PRNewsWire
Neutral
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
2021-09-08 08:05

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an update on the ongoing analyses of the large animal subjects treated with BB-301 in the Pilot Dosing Study.

PRNewsWire
Neutral
Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022
2021-09-08 08:00

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Regulatory Update Highlights: Regarding European Regulatory Interactions: The BB-301 Pilot Dosing Study was viewed as an appropriate dose range finding study The design of the ongoing GLP Biodistribution and Toxicology study was viewed as appropriate to support Phase 1b/2a testing of BB-301 The design of the Phase 1b/2a clinical trial can support the evaluation of BB-301 safety and clinical efficacy in key populations of OPMD patients Regarding U.S. Regulatory Interactions: Benitec has been granted a Type C meeting with the U.S. Food and Drug Administration ("FDA") in the fourth quarter of 2021 Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today announced significant progress regarding the regulatory interactions in Europe required to support advancement of the BB-301 development program towards the Phase 1b/2a clinical study in 2022.

PRNewsWire
Neutral
Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
2021-04-27 21:55

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 3,036,366 shares of common stock of the Company at a price to the public of $4.25 per share, less underwriting discounts and commissions.

PRNewsWire
Neutral
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
2021-04-27 16:44

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that it has entered into an underwriting agreement with H.C.

Pulse2
Positive
BNTC Stock Price Increased 190.28%: Why It Happened
2021-03-23 22:20

The stock price of Benitec Biopharma Inc (NASDAQ: BNTC) increased by 190.28% today. This is why it happened.

Benzinga
Positive
Benitec BioPharma Shares Rally: Technical Levels To Watch
2021-03-23 17:03

Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gained 190.28% in Tuesday's session, closing at $9.26, and was giving back 11.12% to $8.23 in after-hours trading at last check.

Benzinga
Positive
Why DLPN Stock And BNTC Stock Are Popping Off Today
2021-03-23 11:28

Dolphin Entertainment Inc (NASDAQ: DLPN) shares are trading 150% higher after the company announced it launched a non-fungible token (NFT) creation and marketing division. Dolphin Entertainment produces and distributes digital entertainment content.

Loading more news...